Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
No headlines found.
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Globe Newswire (Tue, 14-Mar 5:30 PM ET)
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company A Uniquely Positioned Ticker In The Weeds?
News Direct (Wed, 8-Mar 1:43 PM ET)
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Globe Newswire (Thu, 2-Mar 8:30 AM ET)
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
Globe Newswire (Wed, 1-Mar 8:30 AM ET)
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Globe Newswire (Tue, 28-Feb 4:02 PM ET)
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Globe Newswire (Tue, 21-Feb 8:30 AM ET)
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
Newsfile (Wed, 25-Jan 9:51 PM ET)
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T Target for Small Cell Lung Cancer
Globe Newswire (Wed, 25-Jan 8:30 AM ET)
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Allogene Therapeutics trades on the NASDAQ stock market under the symbol ALLO.
As of March 28, 2023, ALLO stock price climbed to $5.06 with 190,163 million shares trading.
ALLO has a beta of 1.25, meaning it tends to be more sensitive to market movements. ALLO has a correlation of 0.14 to the broad based SPY ETF.
ALLO has a market cap of $729.70 million. This is considered a Small Cap stock.
Last quarter Allogene Therapeutics reported $47,000 in Revenue and -$.66 earnings per share. This fell short of revenue expectation by $-13,000 and exceeded earnings estimates by $.04.
In the last 3 years, ALLO stock traded as high as $55.00 and as low as $4.91.
The top ETF exchange traded funds that ALLO belongs to (by Net Assets): XBI, VTI, VB, IWM, VXF.
ALLO has underperformed the market in the last year with a price return of -47.6% while the SPY ETF lost -11.1%. ALLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.0% and -10.0%, respectively, while the SPY returned +4.2% and +3.1%, respectively.
ALLO support price is $4.83 and resistance is $5.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLO stock will trade within this expected range on the day.